Parkinson Disease 4, Autosomal Dominant Lewy Body Clinical Trials

Recruiting

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

NCT06312176

Conditions: Breast Diseases, Breast Neoplasms, Neoplasms, +4 more
Locations: Ironwood Cancer & Research Centers ( Site 0066) Chandler, Arizona, United States

Banner MD Anderson Cancer Center-Oncology ( Site 0004) Gilbert, Arizona, United States

Providence Medical Foundation-Oncology ( Site 0020) Fullerton, California, United States

Moores Cancer Center ( Site 0059) La Jolla, California, United States

View all 259 locations

View Trial Details

Recruiting

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

NCT06841354

Conditions: Breast Diseases, Breast Neoplasms, Neoplasms, +5 more
Locations: USA Mitchell Cancer Institute ( Site 0090) Mobile, Alabama, United States

Ironwood Cancer & Research Centers ( Site 0036) Chandler, Arizona, United States

City of Hope ( Site 0097) Duarte, California, United States

City of Hope Lennar Foundation Cancer Center ( Site 0099) Irvine, California, United States

View all 268 locations

View Trial Details

Recruiting

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

NCT06966700

Conditions: Breast Diseases, Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms, +6 more
Locations: Banner MD Anderson Cancer Center ( Site 0066) Gilbert, Arizona, United States

Mayo Clinic Cancer Center ( Site 0034) Phoenix, Arizona, United States

University of Arizona Cancer Center ( Site 0035) Tucson, Arizona, United States

Roy and Patricia Disney Family Cancer Center ( Site 0055) Burbank, California, United States

View all 319 locations

View Trial Details

Recruiting

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

NCT06623422

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations: Banner MD Anderson Cancer Center ( Site 0181) Gilbert, Arizona, United States

The University of Arizona Cancer Center - North Campus ( Site 0163) Tucson, Arizona, United States

Providence St. Jude Medical Center ( Site 0106) Fullerton, California, United States

VA Long Beach Healthcare System ( Site 0199) Long Beach, California, United States

View all 241 locations

View Trial Details

Recruiting

A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy

NCT07161414

Conditions: Advanced Solid Tumors, Parkinson Disease 4, Autosomal Dominant Lewy Body
Locations: Research Site Huntersville, North Carolina, United States

Research Site San Antonio, Texas, United States

Research Site Fairfax, Virginia, United States

Research Site Seoul, South Korea

View Trial Details

Recruiting

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

NCT07216703

Conditions: Cervical Cancer, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +12 more
Locations: Florida Cancer Specialists - South ( Site 7001) Fort Myers, Florida, United States

Mount Sinai Comprehensive Cancer Center ( Site 6000) Miami Beach, Florida, United States

Florida Cancer Specialists - East ( Site 7000) West Palm Beach, Florida, United States

Winship Cancer Institute of Emory University ( Site 5005) Atlanta, Georgia, United States

View all 159 locations

View Trial Details

Recruiting

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

NCT06469944

Conditions: Digestive System Diseases, Digestive System Neoplasms, Esophageal Cancer, +10 more
Locations: University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 6927) Tucson, Arizona, United States

UCLA Hematology/Oncology - Santa Monica ( Site 6905) Los Angeles, California, United States

Norton Hospital-Norton Cancer Institute - Downtown ( Site 6900) Louisville, Kentucky, United States

The Cancer and Hematology Centers ( Site 6912) Grand Rapids, Michigan, United States

View all 51 locations

View Trial Details

Recruiting

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

NCT06952504

Conditions: Endometrial Cancer, Endometrial Neoplasms, Female Urogenital Diseases, +11 more
Locations: University of South Alabama, Mitchell Cancer Institute ( Site 6033) Mobile, Alabama, United States

Alaska Women's Cancer Care ( Site 6036) Anchorage, Alaska, United States

CHAO Family Comprehensive Cancer Center and Ambulatory Care ( Site 5014) Irvine, California, United States

University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 6020) Orange, California, United States

View all 260 locations

View Trial Details

Recruiting

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

NCT07252739

Conditions: Malignant Neoplasm, Neoplasms, Parkinson Disease 4, Autosomal Dominant Lewy Body
Locations: Clermont Oncology Center ( Site 0041) Clermont, Florida, United States

Sanford Health Roger Maris Cancer Center ( Site 0039) Fargo, North Dakota, United States

Sanford Cancer Center Oncology Clinic ( Site 0038) Sioux Falls, South Dakota, United States

Fundacion Arturo Lopez Perez ( Site 0167) Santiago, Region M. de Santiago, Chile

View all 38 locations

View Trial Details

Recruiting

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

NCT06170788

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations: Mayo Clinic in Arizona - Phoenix ( Site 0147) Phoenix, Arizona, United States

Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0130) Burbank, California, United States

Cancer Centers of Colorado St. Mary's Regional Hospital ( Site 0132) Grand Junction, Colorado, United States

Mayo Clinic in Florida-Mayo Clinic Comprehensive Cancer Center ( Site 0133) Jacksonville, Florida, United States

View all 220 locations

View Trial Details

Parkinson Disease 4, Autosomal Dominant Lewy Body

Parkinson Disease 4, Autosomal Dominant Lewy Body trial results

Related conditions